Visiongain has launched a new pharma report Hypertension Drugs Market Report: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs).

Rising geriatric population and growing government initiatives to curb hypertension and its complications has boosted the growth of hypertension drugs market however, lack of new drugs in the market to treat hypertension coupled with cutthroat competition among the generic drug manufacturers have led to negative growth of this market.

The lead analyst of the report commented "Approximately, 10-15% of hypertension patients are resistant to current treatment options, where blood pressure is uncontrolled with three or more different classes of hypertension drugs, including a diuretic. Therefore, the need for new treatment strategies to treat the multi-faceted nature of hypertension, including organ protection, is still an area of intensive research."

Leading companies featured in the report include Actelion (now J&J), AstraZeneca, Boehringer Ingelheim GmbH, Daiichi Sankyo, Johnson & Johnson Company. Merck & Co. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.